| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Head of R& D and CMO | Chief Medical Officer | Chief Medical Officer
2 companies
Douglas Kerr is Chief Medical Officer at GBIO, with reported holdings spanning 2 companies. From January 2021 to October 2026, the filings on record show 0 open-market purchases and 14 sales. Douglas Kerr's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.1M at current prices.
Our model assigns Douglas Kerr a middling insider score of 52/100, based on 10 past trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -9.7%.
Douglas Kerr's largest disclosed position is in DYN as Head of R& D and CMO, worth about $3.1M. The DYN filings lean toward selling, a net 17,936 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 5, 2021 | GBIO Generation Bio Co. | Chief Medical Officer | Sale+OE | 14,072 | $30.09 | $423,450.69 | -4.1% | -17.7% | -71.5% | |
| Mar 5, 2021 | GBIO Generation Bio Co. | Chief Medical Officer | Sale+OE | 11,267 | $31.44 | $354,267.16 | -3.3% | - | - | |
| Feb 8, 2021 | GBIO Generation Bio Co. | Chief Medical Officer | Sale+OE | 11,267 | $33.37 | $375,954.36 | -3.3% | - | - | |
| Jan 11, 2021 | GBIO Generation Bio Co. | Chief Medical Officer | Sale+OE | 11,267 | $27.58 | $310,767.87 | -3.3% | - | - |